Infectious Disease
Aspergillosis
33
Pipeline Programs↗
5
Active Trials↗
15
Companies Involved↗
Aspergillosis is a moderately active landscape with 33 programs across 15 companies. The most active players are CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Horizon Therapeutics Ireland DAC, Cidara Therapeutics Inc.. 10 therapies are approved with 7 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 1
No programs
Phase 213
Phase 37
Analysis
Trial Status
49
clinical trials
Completed27 · 55%
Terminated10 · 20%
Recruiting4 · 8%
Withdrawn3 · 6%
Unknown status3 · 6%
Not yet recruiting1 · 2%
Other1 · 2%
Clinical Trials
Trial Activity
49 trials
Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003031·212 enrolled
A Randomized Controlled Trial to Compare the Clinical Outcomes With Six Months of Therapy With Oral Itraconazole Versus Oral Voriconazole for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT04824417·116 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)